CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVROBIO, Inc.(Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced the appointment of Gail M. Farfel, Ph.D., to its Board of Directors...

CUPERTINO, Calif., April 25, 2019 /PRNewswire/ -- DURECT Corporation (DRRX) announced today the appointment of two new members to its board of directors. Dr. Gail M. Farfel, Executive Vice President and Chief Development Officer of Zogenix, Inc., and Judith J. Robertson, most recently Chief Commercial Officer of Aerie Pharmaceuticals, bring to DURECT extensive product development, regulatory and commercialization experience...